Interim report January – September 2021: Profitable growth and Igenomix acquisition
Third quarter: · Sales amounted to SEK 406 (320) million, corresponding to an increase of 27 percent in SEK. Sales increased by 30 percent in local currency. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 162 (134) million, corresponding to a margin of 40 (42) percent. Currency effects positively impacted EBITDA by SEK 1 million. Operating income included non-recurring acquisition-related costs of SEK 8 million. Adjusted EBITDA therefore amounted to SEK 170 million, corresponding to a margin of 42 percent. · Net income amounted to SEK 105 (89)